Know Cancer

or
forgot password

A MULTI-CENTER LONG-TERM FOLLOW-UP STUDY OF PATIENTS WITH LOW-GRADE NON-HODGKIN'S LYMPHOMA PREVIOUSLY TREATED WITH IODINE I 131 TOSITUMOMAB IN STUDIES CP-97-011, CP-98-025, CP-99-032, or CP-99-036


Phase 3
18 Years
N/A
Open (Enrolling)
Both
Non-Hodgkin's Lymphoma

Thank you

Trial Information

A MULTI-CENTER LONG-TERM FOLLOW-UP STUDY OF PATIENTS WITH LOW-GRADE NON-HODGKIN'S LYMPHOMA PREVIOUSLY TREATED WITH IODINE I 131 TOSITUMOMAB IN STUDIES CP-97-011, CP-98-025, CP-99-032, or CP-99-036


Inclusion Criteria:



- Patients must have enrolled in one of the following Corixa sponsored clinical trials:
CP-97-011, CP-98-025, CP-99-032, or CP-99-036 and are >2 years post treatment with
Iodine I 131 Tositumomab.

- Patients must give written informed consent by signing an IRB/ethics committee
approved consent form prior to entry on this follow-up study.

Exclusion Criteria:

- Inability to meet above referenced inclusion criteria.

Type of Study:

Observational

Study Design:

N/A

Principal Investigator

GSK Clinical Trials, MD

Investigator Role:

Study Director

Investigator Affiliation:

GlaxoSmithKline

Authority:

United States: Food and Drug Administration

Study ID:

BEX104528

NCT ID:

NCT00240578

Start Date:

August 2003

Completion Date:

March 2016

Related Keywords:

  • Non-Hodgkin's Lymphoma
  • Low-grade lymphoma
  • Iodine I 131 Tositumomab
  • BEXXAR
  • Long-Term Follow-up
  • Lymphoma
  • Lymphoma, Non-Hodgkin

Name

Location

GSK Clinical Trials Call CenterAurora, Illinois  60506
GSK Clinical Trials Call CenterPittsfield, Massachusetts  01201
GSK Clinical Trials Call CenterAlbany, New York  12208
GSK Clinical Trials Call CenterDes Moines, Iowa  50314
GSK Clinical Trials Call CenterAnn Arbor, Michigan  48109